Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
carvykti save search
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda first approved one treatment for therapy
FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
fda
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -0.27%
H: 4.91%
C: -2.9%
carvykti fda treatment
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-03-15 (Crawled : 19:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda treatment
FDA Adcomm Unanimously Votes in Favor of J&J’s Carvykti Early in Multiple Mye...
Published: 2024-03-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
fda carvykti
EU Panel Backs J&J, Legend’s Carvykti for Second-Line Multiple Myeloma
Published: 2024-02-26 (Crawled : 13:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
carvykti
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
J&J, Legend to Face Adcomm for Carvykti’s Push as Earlier Line MM Treatment
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
treatment
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 0.78%
H: 3.23%
C: 2.76%
carvykti life treatment study
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
Published: 2023-12-12 (Crawled : 01:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
carvykti life treatment
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2023-06-06 (Crawled : 21:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.05%
H: 0.44%
C: 0.27%
carvykti fda license approval treatment application
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
Published: 2023-06-05 (Crawled : 15:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.14%
H: 1.21%
C: 1.0%
carvykti disease treatment risk study
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -1.45%
H: 0.0%
C: -2.77%
carvykti biotech submission
Data Leak Shows J&J’s and Legend’s Carvykti Exceeds Expectations
Published: 2023-04-19 (Crawled : 16:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.61%
H: 0.43%
C: 0.33%
carvykti
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 2.23%
H: 2.09%
C: -4.23%
carvykti treatment biotech study
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.21%
H: 0.19%
C: -0.18%
carvykti treatment study
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2022-05-26 (Crawled : 11:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 1.41%
H: 1.06%
C: -0.48%
carvykti treatment granted approval
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2022-03-25 (Crawled : 13:20) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -1.29%
H: 0.63%
C: -3.83%
carvykti treatment positive chmp
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 09:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.26%
treatment fda fda approval car-t approval cel therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.